==== Front Ann Saudi MedAnn Saudi MedAnnals of Saudi Medicine0256-49470975-4466King Faisal Specialist Hospital and Research Centre 1877963610.5144/0256-4947.2008.374asm-5-374Brief ReportHand-foot syndrome with docetaxel: a five-case series Farhat Mirna H. aEl-Saghir Nagi S. bShamseddine Ali I. b a Department of Internal Medicine, American University of Beirut, Beirut, Lebanon b Department of Hematology/Oncology, American University of Beirut, Beirut, LebanonCorrespondence and reprints: Mirna H. Farhat, MD, Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11-0236/E21, Raid El Solh, Beirut 11070720, Lebanon, T: +961-3-387474, bellanotchi@hotmail.comSep-Oct 2008 28 5 374 377 01 2 2008 Copyright © 2008, Annals of Saudi Medicine2008This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. ==== Body Chemotherapeutic agents may be associated with maculopapular rashes, hyperpigmentation, nail changes, and an acral erythema known as Bergdorf ‘s reaction, palmoplantardysesthesia (PPE), or hand-foot syndrome (HFS).1–5 HFS is a rare cutaneous reaction to certain chemotherapeutic agents that can be severe and debilitating and may cause a delay in chemotherapy administration. Docetaxel has been infrequently reported to cause HFS.1–5 We report the clinical and histopathological details of five cases that occurred with docetaxel in different modes and timing of administration. Patient 1 A 54-year-old woman with breast cancer on adjuvant dose-dense chemotherapy AC-T (Adriamycin, cyclophosphamide, Taxotere) developed severe itching and burning in her palms and soles followed by severe facial erythema 2 days after the second cycle of docetaxel (100mg/m2 IV infusion over 1 hour every 2 weeks). Toxicity was consistent with HFS. The patient refused the last dose of docetaxel. She was referred for radiation therapy and was given letrozole as adjuvant hormonal therapy (Table 1). Patient 2 A 56-year-old female with breast cancer was treated with modified radical mastectomy (MRM) followed by adjuvant dose dense AC-T chemotherapy supported by filgrastim (granulocyle conlony-stimulating factor, G-CSF). Two days after the third cycle of docetaxel (100 mg/m2 IV infusion over 3 hours every 2 weeks), she developed erythema, edema, itching, and and desquamation over the face, feet, and hands (Figure 1). A punch skin biopsy from her upper extremity showed focal parakeratosis in the epidermis with mild spongiosis, scattered dyskeratosis, squamazation of the epithelial cells and maturation disarray. Dermal changes included mild to moderate edema, dilated blood vessels, a mild perivascular and interstitial lymphocytic inflammatory cell infiltrate, neutrophils and nuclear debris (Figure 2). She was diagnosed with HFS and her lesions resolved over 2 weeks. The patient refused the fourth dose of docetaxel and was started on adjuvant hormonal therapy. Patient 3 A 61-year-old female with breast cancer treated with 4 cycles of neoadjuvant AC chemotherapy followed by MRM (cyclophosphamide, doxorubicin). After surgery, the patient was given docetaxel at 100 mg/m2 IV infusion over 1 hour every 3 weeks. Seven days after the third cycle of docetaxel, she developed a non-pruritic skin erythema over the neck, palms, and soles consistent with HFS. The skin lesions progressed to desquamation and then resolved over 2 weeks. A fourth dose of docetaxel was omitted. Patient 4 An 81-year-old female with left breast cancer was treated with mastectomy and adjuvant chemotherapy with 3 cycles of FEC (flurouracil, epirubicin, and cyclophosphamide) followed by docetaxel (100mg/m2) every 3 weeks. After a second cycle of docetaxel, she developed skin erythema, and burning and itching over both hands and feet consistent with HFS. The lesions resolved in one week. Docetaxel was omitted and was replaced by additional cycles of FEC chemotherapy regimen. Patient 5 A 49-year old female with right breast cancer was on adjuvant docetaxel chemotherapy (100mg/m2) infusion over one hour, without any G-CSF support. Four days following the first dose of docetaxel, the patient complained of erythema, a burning sensation and painful swelling over the heels, soles, and palms (Figure 3). She had red plaques over the dorsa of the hands, wrists, and toes. Pathological findings were mild perivascular inflammatory cell infiltrate composed of lymphocytes and neutrophils with nuclear debris. The clinical presentation was consistent with HFS. The patient was treated with emollient creams and topical steroids with gradual resolution of symptoms over 2 weeks. Docetaxel was replaced by paclitaxel and she had no further reaction. DISCUSSION HFS has been described as a cutaneous side effect of cytotoxic chemotherapy with mitotane,6 capecitabine,7,8 cytarabine,9 doxorubicin,10 liposomal daunorubicin,11 liposomal doxorubicin,12 etoposide,13 hydroxyurea,14 gemcitabine and vinorelbine,15 methotrexate,16 and recently, gefitinib.17 Few reports have described HFS as a side effect of docetaxel monotherapy,1–5 or in combination with capecitabine,18 or as a result of concomitant use of pegylated G-CSF.19 Docetaxel-induced acral erythema exhibits a widespread distribution and intense sensation of intolerable pain that may involve areas other than the palms and soles, such as the face and neck as in our patients. Lesions appear as well-defined erythema and edema involving the palmar surfaces. Most reactions occur between day 4 and day 17 after chemotherapy administration. Histologically, HFS shows mild spongiosis, scattered necrotic and dyskeratotic keratinocytes, and vacuolar degeneration of the basal layer,20 as seen in our patients. Dermal changes include dilated blood vessels and papillary edema, whereas a perivascular lymphohistiocytic infiltrate is seen in the epidermis.21 The pathogenesis of HFS involves skin keratinocytes which contain increased levels of the enzyme thymidine phosphorylase needed in the breakdown of 5-fluorouracil related drugs, resulting in enhanced breakdown and accumulation of cytotoxic metabolites in the skin,22 in addition to the vulnerability of tiny capillaries in the palms and soles, which are believed to rupture under pressure from walking or use, releasing the cytotoxic agent and causing an inflammatory reaction.23,24 This makes drugs that have sustained or protracted serum levels such as liposomal doxorubicin and capecitabine more likely to cause HFS. Other possible pathophysiologic mechanisms include dihydropyrimidine dehydrogenase deficiency.25 HFS is generally self-limited. No standard therapy is recommended, but several symptomatic and prophylactic treatments have been used to alleviate symptoms including steroid ointments, occlusive dressings,15 COX-2 inhibitors,26 oral pyridoxine (50–150 mg/day),27,28 blood flow reduction and local hypothermia,29 frozen gloves,30 topical dimethylsulfoxide,31 and oral vitamin E therapy (300 mg/day).32 However, the only proven method for managing HFS is treatment modification, be it interruption or dose reduction.3,21,33 In all of our five patients, HFS lesions were debilitating enough to result in stopping docetaxel therapy and replacing it with other chemotherapy regimens. Patients received palliative therapies consisting of emollient creams, systemic steroids, and pyridoxine 150mg/day over 2 weeks with lesions disappearing gradually over several weeks with no consequences. HFS was not reported in CALGB trial 9741 in which only nonpegylated G-CSF was used, but was reported in cases treated similarly with the addition of pegylated G-CSF.19 The authors suggested that pegylation of filgrastim may have contributed to the HFS. They hypothesized that pegylation of filgrastim augments and prolongs the neutrophil infiltration in some patients, mediating the inflammation observed with HFS. In our present case-series, HFS developed in patients treated with docetaxel in different combinations of therapy: docetaxel preceeded by AC, docetaxel preceeded by FEC, docetaxel monotherapy, and docetaxel with and without G-CSF support, but without any pegylated-G-CSF. Moreover, HFS occurred invariably after a single cycle or multiple cycles of docetaxel. Hence, the dose-dense mode of docetaxel administration was not the cause of HFS as symptoms developed after one cycle only (patient number 5). Observations from the five cases reported highlight docetaxel as an etiologic agent of HFS irrespective of the concomitant use of other chemotherapeutic agents, use of G-CSF in its pegylated or non-pegylated forms, or number of cycles and/or time lapse between cycles. Figure 1 Erythema, edema, itching, and desquamation over the hands two days after the third cycle of docetaxel. Figure 2 Focal parakeratosis in the epidermis with mild spongiosis, scattered dyskeratosis, squamatization of the epithelial cells and maturation disarray (hematoxylin-eosin, × 40). Figure 3 Erythema and swelling over heels and soles 4 days following the first dose of docetaxel. Table 1 Relationship of hand-foot syndrome (HFS) to docetaxel use. Patient 1 2 3 4 5 Adjuvant chemotherapy regimen AC-T AC-T AC FEC-D D Timing of HFS after docetaxel dose 2nd 3rd 3rd 2nd 1st Dose dense docetaxel Yes Yes No No No G-CSF use Yes Yes No No No Peg G-CSF No No No No No Chemotherapy stopped/delayed/modified Yes Yes Yes Yes Yes AC-T: Cyclophosphamide, doxorubicin, paclitaxel; FEC: 5-FU, epirubicin, cyclophosphamide, D: docetaxel ==== Refs REFERENCES 1 Chu CY Yang CH Yang CY Hsiao GH Chiu HC Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel Br J Dermatol 2000 142 808 11 10792238 2 Schrijvers D Van Den Brande J Vermorken JB Supravenous discoloration of the skin due to docetaxel treatment Br J Dermatol 2000 142 1069 70 3 Eich D Scharffetter-Kochanek K Eich HT Tantcheva-Poor I Krieg T Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer Am J Clin Oncol 2002 25 599 602 12478008 4 Zimmerman GC Keeling JH Burris HA Cook G Irvin R Kuhn J Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent Arch Dermatol 1995 131 202 6 7857119 5 Katoh M Kadota M Nishimura Y A case of docetaxel-induced erythrodysesthesia J Dermatol 2004 31 403 406 15187308 6 Zuehlke RL Erythematous eruption of the palms and soles associated with mitotane therapy Dermatologica 1974 148 90 2 4276191 7 Gressett SM Stanford BL Hardwicke F Management of hand-foot syndrome induced by capecitabine J Oncol Pharm Pract 2006 12 131 41 17022868 8 Abushullaih S Saad ED Munsell M Hoff PM Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience Cancer Invest 2002 20 3 10 11853000 9 Crawford JH Eikelboom JW McQuillan A Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia Eur J Haematol 2002 69 315 17 12460237 10 O’Brien ME Wigler N Inbar M Rosso R Grischke E Santoro A Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for firstline treatment of metastatic breast cancer Ann Oncol 2004 15 440 9 14998846 11 Hui YF Cortes JE Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin Pharmacotherapy 2000 20 1221 23 11034047 12 D’Agostino G Ferrandina G Ludovisi M Testa A Lorusso D Gbaguidi N Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer Br J Cancer 2003 89 1180 84 14520442 13 Portal I Cardenal F Garcia-del-Muro X Etoposide-related acral erythema Cancer Chemother Pharmacol 1994 34 181 8194170 14 Silver FS Espinoza LR Hartmann RC Acral erythema and hydroxyurea Ann Intern Med 1983 98 675 15 Laack E Mende T Knuffmann C Hossfeld DK Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine Ann Oncol 2001 12 1761 63 11843256 16 Feizy V Namazi MR Barikbin B Ehsani A Methotrexate-induced acral erythema with bullous reaction Dermatol Online J 2003 9 14 17 Razis E Karina M Karanastassi S Fountzilas G Three case reports of hand-foot syndrome with gefitinib Cancer Invest 2006 24 514 6 16939960 18 Mrozek E Ramaswamy B Young D Rhoades CA Kendra K Allen J Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer Clin Breast Cancer 2006 7 141 5 16800973 19 Bardia A Loprinzi CL Goetz MP Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series J Clin Oncol 2006 24 18 9 20 Gordon KB Tajuddin A Guitart J Kuzel TM Eramo LR VonRoenn J Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy Cancer 1995 75 2169 73 7697608 21 Nagore E Insa A Sanmartin O Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management Am J Clin Dermatol 2000 1 225 34 11702367 22 Asgari MM Haggerty JG McNiff JM Milstone LM Schwartz PM Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors J Cutan Pathol 1999 26 287 94 10472757 23 Lin EH Morris J Chau NK Crane C Wolff R Janjan N Celecoxib attenuated capecitabine induced hand-and foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer Proc Am Soc Clin Oncol 2002 21 (abstr 2364) 24 Wilkes GM Doyle D Palmar-plantar erythrodysesthesia Clin J Oncol Nurs 2005 9 103 6 15751504 25 Saif MW Elfiky A Diasio R Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine Clin Colorectal Cancer 2006 6 219 23 17026792 26 Lin E Morris JS Ayers GD Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity Oncology (Williston Park) 2002 16 suppl 31 7 27 Vukelja SJ Baker WJ Burris HA 3rd Keeling JH Von Hoff D Pyridoxine therapy for palmarplantar erythrodysesthesia associated with taxotere J Natl Cancer Inst 1993 85 1432 33 8102408 28 Vail DM Chun R Thamm DH Garrett LD Cooley AJ Obradovich JE Efficacy of Pyridoxine to ameliorate the cutaneous toxicity associated with Doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model Clin Cancer Res 1998 4 1567 71 9626479 29 Zimmerman GC Keeling JH Lowry M Medina J Von Hoff DD Burris HA Prevention of docetaxel- induced erythrodysesthesia with local hypothermia J Natl Cancer Inst 1994 86 557 8 7907667 30 Scotte F Tourani JM Banu E Peyromaure M Levy E Marsan S Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand J Clin Oncol 2005 23 4424 9 15994152 31 Lopez AM Wallace L Dorr RT Koff M Hersh EM Alberts DS Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmarplantar erythrodysesthesia Cancer Chemother Pharmacol 1999 44 303 6 10447577 32 Kara IO Sahin B Erkisi M Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction Breast 2006 15 414 24 16188440 33 Scheithauer W Blum J Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine Oncology (Williston Park) 2004 18 1161 8 1173 discussion 1173–6, 1181–4 15471200